ARVINAS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
ARVINAS, INC. (ARVN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of -$200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-24
- ARVINAS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was -$200.00K, a 125.00% decline from fiscal 2024.
- ARVINAS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $800.00K, a 60.00% increase from fiscal 2023.
- ARVINAS, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $500.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | -$200.00K 10-K · filed 2026-02-24 |
| 2024-12-31 | $800.00K 10-K · filed 2026-02-24 |
| 2023-12-31 | $500.00K 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |